Federica Ferrari

Scopus Publications

Diagnostic and prognostic value of blood neurofilament light chain in ischemic stroke: an individual patient data meta-analysis
Lorenzo Barba, Michele Romoli, Pascal Benkert, Lisa Hofer, Luis F. Maia, Alexandre Dias, Rui Magalhães, Catarina Guedes Vaz, Jan Emmerich, Kristian Barlinn, Christoph Vollmuth, Hermann Neugebauer, Marta Truffi, Carlo Morasso, Federica Ferrari, Grant O’Connell, Steffen Tiedt, Dilara Moumin, Thomas Gattringer, Markus Kneihsl, Michael Khalil, Annie Pedersen, Tara M. Stanne, Sofia Furutjäll, Christina Jern, Helle H. Nielsen, Kate L. Lambertsen, Mi-Yeon Eun, June Woo Ahn, Poosanu Thanapornsangsuth, Wanakorn Rattanawong, Fani Pujol-Calderón, Henrik Zetterberg, Kaj Blennow, Marianne Hahn, Timo Uphaus, Klaus Gröschel, Valentina Tudisco, Julian Klingbeil, Arthur Guthknecht, Samir Abu-Rumeileh, Simona Sacco, Matteo Foschi, Lucio D’Anna, Jens Kuhle, Markus Otto, Valeria Caso
Journal of Neurology, 2026
Impact of cancer on outcomes following breakthrough ischaemic stroke on oral anticoagulants for atrial fibrillation: insights from the ASPERA-R study
Matteo Foschi, Federico De Santis, Francesca Gabriele, Lucio D'Anna, Andrea Zini, et al.
European Stroke Journal, 2026
BACKGROUND: Breakthrough ischaemic stroke during oral anticoagulation (OAC) for atrial fibrillation (AF) represents a major therapeutic challenge, especially in patients with cancer, who face competing risks of thrombosis and bleeding. This study investigated the impact of cancer on 90-day outcomes after ischaemic stroke on OAC. PATIENTS AND METHODS: We analysed patients with AF who experienced ischaemic stroke while on continuous OAC enrolled in the international retrospective ASPERA-R study, comprising 35 stroke centres across 9 countries. Inverse probability weighting was applied to adjust for baseline imbalances, and weighted Cox, ordinal logistic and generalised linear models were used to estimate adjusted 90-day risks for the primary (ischaemic stroke or TIA), secondary (mRS shift, vascular/all-cause death) and safety (moderate-to-severe bleeding, ICH, 24-h haemorrhagic transformation) outcomes. RESULTS: Among 1649 included patients (mean age 78.0 ± 10.7 years; 45.8% male), 247 (15.0%) had cancer, of whom 87 (35.2%) had active cancer and 160 (64.8%) were in remission. After weighting, patients with cancer had a significantly higher 90-day risk of new ischaemic stroke or TIA (8.2% vs 2.8%; adjusted hazard ratio [aHR] 2.56; 95% CI, 1.59-4.13; P < .001) and worse 90-day mRS score distribution (adjusted odds ratio 1.29; 95% CI, 1.08-1.54; P = .005) than those without cancer. Active cancer conferred a > 4-fold higher risk of new ischaemic stroke or TIA (HR 4.48, 95% CI, 2.46-8.13; P < .001) and nearly 3-fold higher risk of moderate-to-severe bleeding (HR 2.77; 95% CI, 1.30-5.88; P = .008). Patients with cancer in remission showed increased ischaemic risk (HR 2.60; 95% CI, 1.59-5.25; P = .001) but not bleeding risk. Haematological malignancies carried a higher risk for both new ischaemic stroke or TIA (HR 3.06; 95% CI, 1.69-5.54; P = .001) and moderate-to-severe bleeding (HR 3.47, 95% CI, 1.57-7.70; P = .006) compared to solid malignancies. CONCLUSION: Cancer, particularly active and haematological malignancies, substantially worsens 90-day prognosis after breakthrough stroke on OAC, underscoring the need for refined risk stratification and tailored secondary prevention. TRIAL REGISTRATION: URL: www.clinicaltrials.gov; Unique identifier: NCT06823466.
Case Report: Intensive multidisciplinary motor-cognitive rehabilitation treatment in Gerstmann–Sträussler–Scheinker syndrome
A. De Laurenzis, C. Siri, L. Bandirali, L. Lucca, L. Covaia, F. Ferrari, C. Zaffina, M. Canesi
Frontiers in Rehabilitation Sciences, 2026
Gerstmann–Sträussler–Scheinker syndrome (GSS) is a genetic, autosomal dominant prion brain disease that causes ataxia and slow cognitive decline. Herein, we describe a 34-year-old woman (S.C.B.) diagnosed with GSS (variant Pro102Leu). In 2018, she presented with gait instability without falls, early fatigue, and dizziness; after 3 years, urinary incontinence, initial insomnia and rapid-eye movement sleep behavior disorder, writing difficulties, and occasional dysphagia had appeared. S.C.B. was admitted to the Neurorehabilitation Unit due to the progressive worsening of her balance and walking ability [Timed Up and Go (TUG): not evaluated; Berg Balance Scale (BERG): 5/56]. At admission, neurological, neuropsychological, physiotherapeutic, occupational, and speech assessments were performed. She was completely dependent in basic (ADL) and instrumental activities of daily living (iADL) (ADL: 5/6; iADL: 4/8; Barthel Index: 60); furthermore, moderate cognitive decline and depressive symptoms were observed. After 4 weeks of intensive motor-cognitive rehabilitation treatment , an improvement was observed in all the intervention areas, leading to a global gain in autonomy (TUG: 1 min 50 s; BERG: 10/56; Barthel Index: 70). This case report highlights the importance of tailored motor-cognitive rehabilitation and how these interventions can enhance patients’ quality of life and their ability to cope with their symptoms. In conclusion, this case contributes to a broader understanding of treatment options that clinicians can propose to patients.
Continuation vs Switching Direct Oral Anticoagulant Therapy after Breakthrough Stroke
Lucio D’Anna, Francesca Gabriele, Raffaele Ornello, Andrea Zini, Matteo Paolucci, Stefano Forlivesi, Ludovica Migliaccio, Maria Maddalena Viola, Angelo Cascio Rizzo, Maria Sessa, Ghil Schwarz, Rachele Tortorella, Gabriele Prandin, Soma Banerjee, Gurav Desai, Leonardo Pantoni, Francesco Mele, Giuseppe Scopelliti, Ilaria Cova, Mariarosaria Valente, Domenico Maisano, Maria Rosaria Bagnato, Giovanni Di Mauro, Francesca Bernocchi, Martina Gaia Di Donna, Barbara Casolla, Marie-Helene Mahagne, Marie-Eve Amoretti, Lucille Morgan, Laura González, Ricardo Rigual, Blanca Fuentes, Carlos Hervás, Paolo Candelaresi, Vincenzo Andreone, Antonio De Mase, Emanuele Spina, Diana Aguiar de Sousa, Mariana Almudi Souza, Alberto Fior, Miguel Serôdio, Pietro Caliandro, Aurelia Zauli, Giuseppe Reale, Ahmed Abdelalim, Sandra Ahmed, Samah Ali Ismail, Liqun Zhang, Tara Latimer, Muhammad Elboghday, Ahmed El Bassiouny, Tamer Roushdy, Hossam Shokri, Federica Ferrari, Nicola Davide Loizzo, Federico Mazzacane, Maria Guarion, Valentina Barone, Paola Forti, Giuseppe Rinaldi, Marco Rossi, Vincenzo Laterza, Giovanni Frisullo, Pier Andrea Rizzo, Aldobrando Broccolini, Marina Mannino, Valeria Terruso, Marcella Caggiula, Simona Scalise, Ana Catarina Fonseca, Bernardo Antunes, Hrvoje Budincevic, Petra Crnac, Giovanna Viticchi, Mauro Silvestrini, Lorenzo Barba, Viktoria Musienko, Piergiorgio Lochner, Benjamin Landau, Sandeep Buddha, Roumeisa Khalil, Maria Grazia Piscaglia, Elena Minguzzi, Marialuisa Zedde, Ahmed Nasreldein, Luisa Vinciguerra, Luis Costa, Ahmed ElsaidElsayed, Mona Al Banna, Laura Tudisco, Maria Giulia Mosconi, Giovanni Merlino, Federico De Santis, Simona Sacco, Matteo Foschi
JAMA Network Open, 2026
Importance Management after an ischemic stroke occurring despite direct oral anticoagulant (DOAC) therapy for atrial fibrillation (AF) varies widely. Switching anticoagulation is common in clinical practice, although evidence supporting this strategy is limited. Objective To evaluate whether continuation of treatment with the same DOAC was noninferior to switching oral anticoagulant therapy with respect to 90-day clinical outcomes. Design, Setting, and Participants This multicenter registry-based cohort study with an emulated target trial design included consecutive adult patients with AF who experienced a breakthrough ischemic stroke while receiving uninterrupted DOAC therapy and resumed anticoagulation therapy thereafter. Patients were enrolled between February 2020 and February 2025, across 35 stroke centers in 9 countries in Europe and North Africa, with a standardized 90-day follow-up. The dataset was locked on September 1, 2025. A noninferiority comparison of switching vs continuation strategies was performed. Baseline confounding was addressed using inverse probability of treatment weighting (IPTW). The primary noninferiority margin was an absolute risk difference of 3.0 percentage points in 90-day net clinical benefit. Exposure The intervention group switched to treatment with a different DOAC or vitamin K antagonist; the comparator group continued therapy with the prestroke DOAC. Main Outcomes and Measures The primary outcome was 90-day net clinical benefit, defined as recurrent ischemic stroke and moderate to severe bleeding. Secondary outcomes included recurrent ischemic events, symptomatic intracerebral hemorrhage, moderate to severe extracranial bleeding, all-cause mortality, and vascular death. Results Among 1006 patients included in the analysis (median age, 80.4 [IQR, 73.4-85.4] years; 503 female [50.0%] and 503 [50.0%] male), 463 (46.0%) continued the same DOAC therapy and 543 (54.0%) switched therapy. After IPTW adjustment, the 90-day net clinical benefit was 4.9% with switching and 5.1% with continuation, corresponding to a risk difference of −0.3 percentage points (90% CI, −2.7 to 2.1 percentage points), meeting the prespecified noninferiority criterion. For recurrent ischemic events and bleeding outcomes, the absolute differences were within the predefined noninferiority margins. Noninferiority was not demonstrated for all-cause or vascular mortality. Conclusions and Relevance In patients with breakthrough ischemic stroke during DOAC therapy, switching anticoagulation treatment was not associated with clinically meaningful short-term benefit compared with continuation. These findings suggest that switching does not provide additional benefit compared with continuing treatment with the same DOAC. Randomized clinical trials are needed to identify strategies to improve secondary prevention after a breakthrough ischemic stroke.
Competing Stroke Etiologies and Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants in Patients With Atrial Fibrillation
Matteo Foschi, Federico De Santis, Francesca Gabriele, Raffaele Ornello, Lucio D'Anna, Andrea Zini, Matteo Paolucci, Stefano Forlivesi, Ludovica Migliaccio, Maria Maddalena Viola, Angelo Cascio Rizzo, Maria Sessa, Ghil Schwarz, Rachele Tortorella, Soma Banerjee, Gaurav Desai, Kazi Farhad Ahmed, Gabriele Prandin, Leonardo Pantoni, Francesco Mele, Giuseppe Scopelliti, Ilaria Cova, Mariarosaria Valente, Domenico Maisano, Luca Antonelli, Maria Rosaria Bagnato, Giovanni Di Mauro, Francesca Bernocchi, Martina Gaia Di Donna, Barbara Casolla, Perla Mazloum, Corrado Campisi, Agathe Caraux, Laura González-Martín, Ricardo Rigual, Blanca Fuentes, Carlos Hervás-Testal, Paolo Candelaresi, Vincenzo Andreone, Antonio De Mase, Emanuele Spina, Diana Aguiar De Sousa, Mariana Almudi Souza, Alberto Fior, Miguel Serôdio, Pietro Caliandro, Aurelia Zauli, Giuseppe Reale, Ahmed Abdelalim, Sandra Ahmed, Samah Ali Ismail, Liqun Zhang, Tara Latimer, Muhammad Elboghdady, Ahmed Elbassiouny, Tamer Roushdy, Hossam Shokri, Federica Ferrari, Nicola D. Loizzo, Federico Mazzacane, Maria Guarino, Valentina Barone, Paola Forti, Giuseppe Rinaldi, Marco Vito Rossi, Vincenzo Laterza, Giovanni Frisullo, Pier Andrea Rizzo, Aldobrando Broccolini, Marina Mannino, Valeria Terruso, Marcella Caggiula, Annalisa Rizzo, Ana Catarina Fonseca, Bernardo Antunes, Ana M. Barbosa, Hrvoje Budincevic, Petra Crnac, Giovanna Viticchi, Mauro Silvestrini, Lorenzo Barba, Viktoria Musienko, Markus Otto, Piergiorgio Lochner, Benjamin Landau, Sandeep Buddha, Roumeisa Khalil, Maria Grazia Piscaglia, Elena Minguzzi, Marialuisa Zedde, Ahmed Nasreldein, Luisa Vinciguerra, Luis Rufo Costa, Ahmed Elsaid Elsayed, Mona AlBanna, Laura Tudisco, Maria Giulia Mosconi, Alexandros A. Polymeris, Giovanni Merlino, Simona Sacco
Neurology, 2026
BACKGROUND AND OBJECTIVES: Patients with atrial fibrillation (AF) who experience an ischemic stroke despite oral anticoagulation (OAC) face a high risk of recurrence and bleeding. We aimed to compare 90-day outcomes between patients with and without competing stroke etiologies after a breakthrough ischemic stroke while on OAC for AF. METHODS: ASPERA-R retrospectively enrolled adults (>18 years) with AF who experienced a breakthrough ischemic stroke, defined as either first or recurrent event, occurring on continuous OAC (last intake ≤48 hours), across 35 centers from February 2020 to February 2025. Patients' eligibility required imaging-confirmed ischemic stroke, baseline vessel imaging, and a standardized 90-day follow-up. Patients with inadequate anticoagulant dosing or poor adherence were excluded. Competing etiologies were defined as any additional mechanism coexisting with cardioembolism and plausibly contributing to the index stroke. The primary outcome was 90-day recurrent ischemic stroke; secondary outcomes included modified Rankin Scale shift, myocardial infarction, and vascular and all-cause death. Bleedings were also evaluated. We performed inverse probability weighting to balance baseline covariates and applied Cox or regression models to compare outcomes. RESULTS: = 0.020). Other outcomes did not differ. DISCUSSION: One in 4 patients with AF and breakthrough ischemic stroke on OAC had competing etiologies, most often large artery atherosclerosis. These patients showed higher risk of recurrent stroke, functional dependence, mortality, and bleeding, highlighting the need for development of individualized secondary prevention. Main study limitations include observational retrospective design and incomplete data on on-treatment anticoagulation quality. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT06823466.
Sex Differences in Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants for Atrial Fibrillation: An ASPERA-R Inverse Probability Weighted Analysis
Matteo Foschi, Lucio D’Anna, Francesca Gabriele, Raffaele Ornello, Andrea Zini, Matteo Paolucci, Stefano Forlivesi, Ludovica Migliaccio, Maria Maddalena Viola, Angelo Cascio Rizzo, Maria Sessa, Ghil Schwarz, Rachele Tortorella, Soma Banerjee, Gaurav Desai, Muhammad Jaffar, Gabriele Prandin, Leonardo Pantoni, Francesco Mele, Giuseppe Scopelliti, Ilaria Cova, Mariarosaria Valente, Domenico Maisano, Luca Antonelli, Maria Rosaria Bagnato, Giovanni Di Mauro, Francesca Bernocchi, Martina Gaia Di Donna, Barbara Casolla, Perla Mazloum, Chiara Bruno, Baptiste Alvarez, Laura González‐Martín, Ricardo Rigual, Blanca Fuentes, Carlos Hervás, Paolo Candelaresi, Vincenzo Andreone, Antonio De Mase, Emanuele Spina, Diana Aguiar de Sousa, Mariana Almudi Souza, Alberto Fior, Miguel Serôdio, Pietro Caliandro, Aurelia Zauli, Giuseppe Reale, Ahmed Abdelalim, Sandra Ahmed, Nourhan Mohamed Soliman, Liqun Zhang, Tara Latimer, Muhammad Elboghday, Ahmed Aly Elbassiouny, Tamer Roushdy, Hossam Shokri, Federica Ferrari, Nicola Davide Loizzo, Federico Mazzacane, Maria Guarino, Valentina Barone, Paola Forti, Giuseppe Rinaldi, Marco Vito Rossi, Vincenzo Laterza, Giovanni Frisullo, Pier Andrea Rizzo, Aldobrando Broccolini, Marina Mannino, Valeria Terruso, Marcella Caggiula, Guglielmo Lucchese, Ana Catarina Fonseca, Bernardo Antunes, Ana M Barbosa, Hrvoje Budincevic, Petra Crnac, Giovanna Viticchi, Mauro Silvestrini, Lorenzo Barba, Viktoria Musienko, Markus Otto, Piergiorgio Lochner, Benjamin Landau, Sandeep Buddha, Roumeisa Khalil, Maria Grazia Piscaglia, Elena Minguzzi, Marialuisa Zedde, Ahmed Nasreldein, Luisa Vinciguerra, Luis Costa, Ahmed Elsaid Elsayed, Mona AlBanna, Laura Tudisco, Maria Giulia Mosconi, Giovanni Merlino, Alexandros Polymeris, Federico De Santis, Simona Sacco
Journal of the American Heart Association, 2026
Background Sex‐specific outcomes after breakthrough ischemic stroke on oral anticoagulation (OAC) are unexplored. We compared 90‐day outcomes by sex and explored modifiers. Methods ASPERA‐R (Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants retrospective cohort; NCT06823466) was an international, multicenter, retrospective study enrolling adults (aged >18 years) with breakthrough ischemic stroke on OAC for atrial fibrillation. Primary outcome was 90‐day return to baseline neurologic function (modified Rankin Scale [mRS] score 0–1 maintained if prestroke 0–1; or same/lower mRS score if prestroke ≥2). Secondary outcomes were 90‐day mRS shift, recurrent ischemic stroke/transient ischemic attack, myocardial infarction, and all‐cause and vascular death. Safety outcomes included 90‐day moderate‐to‐severe bleeding, intracranial hemorrhage, 24‐hour hemorrhagic transformation, and 24‐hour symptomatic intracranial hemorrhage. We applied inverse probability weighting and regression models to compare outcomes. Prespecified subgroup analysis tested sex‐specific interactions. Results We included 1649 patients (women, 52.2%; mean±SD age, 78.0±10.7 years). Women were older (80.2±9.6 versus 76.3±10.8 years; unweighted standardized mean difference=0.376), had higher baseline National Institutes of Health Stroke Scale score (13 [interquartile range, 9–19] versus 9 [interquartile range, 4–17]; unweighted standardized mean difference=0.227), and worse prestroke mRS score (unweighted standardized mean difference=0.237). After weighting, women were less likely to return to baseline neurologic function (35.2% versus 42.7%; adjusted risk ratio, 0.82 [95% CI, 0.71–0.96]; P =0.015), had worse mRS distribution (adjusted odds ratio, 1.17 [95% CI, 1.01–1.37]; P =0.043), and had higher recurrent ischemic stroke/transient ischemic attack (4.8% versus 2.8%; adjusted hazard ratio [HR], 1.70 [95% CI, 1.01–2.86]; P =0.045). Women showed a trend toward more moderate‐to‐severe bleeding (4.6% versus 2.8%; adjusted HR, 1.63 [95% CI, 0.96–2.72]; P =0.070). Subgroup analyses revealed significant sex interactions for OAC type, competing cause, endovascular treatment, and OAC restart. Conclusions Women had worse 90‐day outcomes than men after breakthrough ischemic stroke on OAC for atrial fibrillation, highlighting the need for sex‐aware management.
Role of JNK3 signaling in acute ischemic stroke cerebroprotection: A systematic review
Federica Ferrari, Federico Mazzacane, Beatrice del Bello, Anna Cavallini, Domenico Raimondo, Tiziana Borsello
Biomedicine and Pharmacotherapy, 2025
Ischemic stroke lacks clinically proven cerebroprotectants, partly because candidate targets have not been evaluated with rigorous translational pipelines. The aim of this study was to perform a systematic review about the potential role of the brain-enriched JNK3 signaling as a therapeutic target for acute ischemic stroke. A PRISMA-guided systematic search of PubMed, EMBASE and Scopus was performed up to October 2024. The research was limited to original research articles published in extenso on Institute for Scientific Information (ISI) Journals and written in English. Fifty-six studies met the inclusion criteria, all preclinical with a predominance for rodent models of global transient ischemia, with sparse representation of focal or large-animal models. Although the heterogeneous outcomes of the included studies, convergent evidence showed that JNK3 drives post-ischemic injury through (i) GluR6/NMDAR-PSD-95-MLK3 excitotoxic scaffolds, (ii) ASK1-initiated oxidative cascade, (iii) mitochondrial Bax/cytochrome-c apoptosis, (iv) ceramide synthesis and autophagy dysregulation, and (v) release from PI3K-AKT or HO-1 scaffold brakes. Collectively, literature supports JNK3 as a pleiotropic, druggable hub whose early blockade affords robust cerebroprotection, but translation into the clinical settings will require isoform-selective, brain-penetrant compounds evaluated in experimental conditions that more closely mirror clinical reality. Speculatively, future advances may derive from highly specific JNK3 inhibitors capable of targeting vulnerable neuronal populations within ischemic regions. When combined with optimized delivery systems and personalized therapeutic strategies, such agents may ultimately contribute to redefining the cerebroprotective landscape in stroke therapy. • First systematic review on JNK3 signaling in acute ischemic stroke. • Evidence from 56 studies highlights JNK3 as a key stroke physiopathology mediator. • JNK3 integrates excitotoxic, oxidative, and apoptotic stress cascades. • Targeting ASK1–MLK3–JNK3 axis consistently reduces ischemic injury. • Isoform-selective JNK3 inhibitors hold promise for translational stroke therapy.
Adapting foundation models for rapid clinical response: intracerebral hemorrhage segmentation in emergency settings
Alessia Gerbasi, Federico Mazzacane, Federica Ferrari, Beatrice Del Bello, Anna Cavallini, Riccardo Bellazzi, Silvana Quaglini
Scientific Reports, 2025
Intracerebral hemorrhage (ICH) is a medical emergency that demands rapid and accurate diagnosis for optimal patient management. Hemorrhagic lesions' segmentation on CT scans is a necessary first step for acquiring quantitative imaging data that are becoming increasingly useful in the clinical setting. However, traditional manual segmentation is time-consuming and prone to inter-rater variability, creating a need for automated solutions. This study introduces a novel approach combining advanced deep learning models to segment extensive and morphologically variable ICH lesions in non-contrast CT scans. We propose a two-step methodology that begins with a user-defined loose bounding box around the lesion, followed by a fine-tuned YOLOv8-S object detection model to generate precise, slice-specific bounding boxes. These bounding boxes are then used to prompt the Medical Segment Anything Model for accurate lesion segmentation. Our pipeline achieves high segmentation accuracy with minimal supervision, demonstrating strong potential as a practical alternative to task-specific models. We evaluated the model on a dataset of 252 CT scans demonstrating high performance in segmentation accuracy and robustness. Finally, the resulting segmentation tool is integrated into a user-friendly web application prototype, offering clinicians a simple interface for lesion identification and radiomic quantification.
Cherishing Professional Success and Personal Fulfillment: Resilience as a Pivotal Leadership Competency for Clinical Pharmacologists and Beyond
Karthik Venkatakrishnan, Jing ‘Daisy’ Zhu, Federica Ferrari, Krista Levy, Beth Kennedy
Journal of Clinical Pharmacology, 2025
Resilience is a critical leadership competency directly linked to engagement, sustainable innovation, and productivity. This Commentary presents resilience concepts using the Benatti Resiliency Model®, which comprises five inter‐related dimensions: Well‐being, Self‐awareness, Brand, Connection, and Innovation. Trust is discussed as a critical leadership competency, with three levels: self‐trust, trust in relationships at the team level, and community trust. The concept of Ikigai, representing the intersection of what one loves, what one is good at, what the world needs, and what one can be paid for, is discussed as a framework for self‐awareness, brand development, development planning, and mentoring. Time and energy management using the Eisenhower matrix is highlighted as a strategy to build resilience, manage stress, enhance productivity, and prevent burnout. Taken together, the strategies discussed in this commentary are intended to unlock the transformative potential of resilience for sustainable innovation and impact within and beyond the dynamic and interdisciplinary field of clinical pharmacology, ultimately enabling professional success and personal fulfillment.
Stress hyperglycemia indexes and early neurological deterioration in spontaneous intracerebral hemorrhage
Carmelo Tiberio Currò, Federica Ferrari, Giovanni Merlino, Stefan Moraru, Francesco Bax, Fedra Kuris, Lorenzo Nesi, Mariarosaria Valente, Elena Ballante, Nicola d’Altilia, Cristina Rascunà, Andrea Morotti, Federico Mazzacane, Anna Maria Cavallini
Neurological Sciences, 2025
Aim To evaluate the relationship of early neurological deterioration (END) with admission glycemia (aG) and new stress hyperglycemia indexes in spontaneous intracerebral hemorrhage (ICH) patients. Methods The present retrospective study included 171 ICH patients from two stroke centers. END was defined as an increase ≥ 4 points in National Institutes of Health Stroke Scale and/or a decrease ≥ 2 points in Glasgow Coma Scale within 72 hours from admission. The included stress hyperglycemia indexes were glycemic gap (GGAP), stress hyperglycemia ratio (SHR), and glucose-glycated hemoglobin ratio. GGAP was calculated as aG – 28,7*glycated hemoglobin + 46,7; SHR as aG / (28,7*glycated hemoglobin – 46,7); Glucose-glycated hemoglobin ratio as aG / glycated hemoglobin. We performed univariate and multivariate analyses for END. The receiver operating characteristic curves were built for END-related glycemic measures; area under curves (AUC) were calculated and compared. The optimized threshold values were calculated, and significant glycemic measures were dichotomized. Univariate and multivariate analyses were performed for the dichotomized measures. Results END was present in 21 patients (12.3%) and was significantly associated with GGAP, SHR and glucose-glycated hemoglobin ratio, but not with aG. The AUC of the three stress hyperglycemia indexes did not differ significantly. The optimized cutoffs were 35.68 (sensitivity 0.47, specificity 0.81), 1.15 (sensitivity 0.62, specificity 0.68), and 26.67(sensitivity 0.43, specificity 0.80) for GGAP, SHR, and glucose-glycated hemoglobin ratio respectively. END was also associated with all stress hyperglycemia indexes expressed as categorical variables. Conclusion GGAP, SHR, and glucose-glycated hemoglobin ratio were predictors of END in ICH patients.
Intracranial Nonstenosing Atherosclerotic Plaques Assessed With Vessel Wall MRI in Patients With Embolic Stroke of Undetermined Source
Federico Mazzacane, Beatrice Del Bello, Elisa Rognone, Carlo Asteggiano, Federica Ferrari, Alessandra Persico, Alfredo Costa, Roberto De Icco, Andrea Morotti, Anna Pichiecchio, Anna Cavallini
Neurology, 2025
Apomorphine Subcutaneous Infusion Likely Induced Acute Thrombocytopenia in a Patient with Parkinson's Disease and Motor Fluctuations
Maria Magdalena Pocora, Micol Avenali, Michele Giovanni Croce, Federica Ferrari, Francesca Valentino, Claudio Pacchetti, Cristina Tassorelli, Roberta Zangaglia
Movement Disorders Clinical Practice, 2025
Impact of CYP2C19 Genotype on Efficacy and Safety of Clopidogrel-based Antiplatelet Therapy in Stroke or Transient Ischemic Attack Patients: An Updated Systematic Review and Meta-analysis of Non-East Asian Studies
Sarah Cargnin, Federica Ferrari, Salvatore Terrazzino
Cardiovascular Drugs and Therapy, 2024
Effects of Chronic Hypertension on the Energy Metabolism of Cerebral Cortex Mitochondria in Normotensive and in Spontaneously Hypertensive Rats During Aging
Roberto Federico Villa, Federica Ferrari, Antonella Gorini
Neuromolecular Medicine, 2024
Medial intracranial carotid artery calcifications and hematoma expansion in deep intracerebral hemorrhage
Federico Mazzacane, Stefan Moraru, Beatrice Del Bello, Federica Ferrari, Erica Ferro, Alessandra Persico, Jawed Nawabi, Alessandro Padovani, Anna Cavallini, Andrea Morotti
Annals of Clinical and Translational Neurology, 2024
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting
Gloria Vaghi, Andrea Morotti, Elisa Maria Piella, Micol Avenali, Daniele Martinelli, Silvano Cristina, Marta Allena, Valentina Grillo, Michele Corrado, Federico Bighiani, Francescantonio Cammarota, Alessandro Antoniazzi, Federica Ferrari, Federico Mazzacane, Anna Cavallini, Anna Pichiecchio, Elisa Rognone, Luca Martinis, Luca Correale, Stefano Filippo Castiglia, Dante Trabassi, Mariano Serrao, Cristina Tassorelli, Roberto De Icco
Scientific Reports, 2024
Acute amnestic syndrome in fornix lesions: a systematic review of reported cases with a focus on differential diagnosis
F. Mazzacane, F. Ferrari, A. Malvaso, Y. Mottese, M. Gastaldi, A. Costa, A. Pichiecchio, A. Cavallini
Frontiers in Neurology, 2024
Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients
Federica Ferrari, Daniela Rossi, Alessandra Ricciardi, Carlo Morasso, Liliana Brambilla, Sara Albasini, Renzo Vanna, Chiara Fassio, Tatjana Begenisic, Marianna Loi, Daniela Bossi, Alberto Zaliani, Elisa Alberici, Claudio Lisi, Andrea Morotti, Anna Cavallini, Federico Mazzacane, Antonio Nardone, Fabio Corsi, Marta Truffi
Journal of Cerebral Blood Flow and Metabolism, 2023
Intracranial carotid artery calcification morphology differs in patients with lacunar and nonlacunar acute ischemic strokes
Federico Mazzacane, Beatrice Del Bello, Federica Ferrari, Alessandra Persico, Elisa Rognone, Anna Pichiecchio, Alessandro Padovani, Anna Cavallini, Andrea Morotti, Francesco Arba
European Journal of Neurology, 2023
Brain bioenergetics in chronic hypertension: Risk factor for acute ischemic stroke
Federica Ferrari, Roberto Federico Villa
Biochemical Pharmacology, 2022
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, Roberto Federico Villa
Pharmacology and Therapeutics, 2022
Clonidine and Brain Mitochondrial Energy Metabolism: Pharmacodynamic Insights Beyond Receptorial Effects
Roberto Federico Villa, Antonella Gorini, Federica Ferrari
Neurochemical Research, 2022
Hyperglycemia in acute ischemic stroke: Physiopathological and therapeutic complexity
RobertoFederico Villa, Federica Ferrari, Antonio Moretti
Neural Regeneration Research, 2022
Synaptic ATPases and energy metabolism in the nervous system: Roles and changes during aging
Roberto Federico Villa, Federica Ferrari
Factors Affecting Neurological Aging Genetics Neurology Behavior and Diet, 2021
Use of cangrelor in cervical and intracranial stenting for the treatment of acute ischemic stroke: A "real life" single-center experience
A. Cervo, F. Ferrari, G. Barchetti, L. Quilici, M. Piano, E. Boccardi, G. Pero
American Journal of Neuroradiology, 2020
The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs
Federica Ferrari, Antonio Moretti, Roberto Federico Villa
Pharmacological Research, 2020
Synaptic ATPases system of rat frontal cerebral cortex during aging
Federica Ferrari, Paola Viscardi, Antonella Gorini, Roberto Federico Villa
Neuroscience Letters, 2019
Glutamate metabolism in cerebral mitochondria after ischemia and post-ischemic recovery during aging: relationships with brain energy metabolism
Federica Ferrari, Antonella Gorini, Siegfried Hoyer, Roberto Federico Villa
Journal of Neurochemistry, 2018
Post-stroke depression: Mechanisms and pharmacological treatment
Roberto Federico Villa, Federica Ferrari, Antonio Moretti
Pharmacology and Therapeutics, 2018
The Neurobiology of Depression: an Integrated Overview from Biological Theories to Clinical Evidence
F. Ferrari, R. F. Villa
Molecular Neurobiology, 2017
Mitochondrial energy metabolism of rat hippocampus after treatment with the antidepressants desipramine and fluoxetine
Roberto Federico Villa, Federica Ferrari, Laura Bagini, Antonella Gorini, Nicoletta Brunello, Fabio Tascedda
Neuropharmacology, 2017
Effect of desipramine and fluoxetine on energy metabolism of cerebral mitochondria
Roberto Federico Villa, Federica Ferrari, Antonella Gorini, Nicoletta Brunello, Fabio Tascedda
Neuroscience, 2016
Pharmacological therapy of acute ischaemic stroke: Achievements and problems
Antonio Moretti, Federica Ferrari, Roberto F. Villa
Pharmacology and Therapeutics, 2015
Functional proteomics of synaptic plasma membrane ATP-ases of rat hippocampus: Effect of l-acetylcarnitine and relationships with Dementia and Depression pathophysiology
Federica Ferrari, Antonella Gorini, Roberto Federico Villa
European Journal of Pharmacology, 2015
Energy Metabolism of Synaptosomes from Different Neuronal Systems of Rat Cerebellum During Aging: A Functional Proteomic Characterization
Federica Ferrari, Antonella Gorini, Roberto Federico Villa
Neurochemical Research, 2015
Neuroprotection for ischaemic stroke: Current status and challenges
Antonio Moretti, Federica Ferrari, Roberto F. Villa
Pharmacology and Therapeutics, 2015
Functional proteomics related to energy metabolism of synaptosomes from different neuronal systems of rat hippocampus during aging
Roberto F. Villa, Federica Ferrari, Antonella Gorini
Journal of Proteome Research, 2013
Energy metabolism of cerebral mitochondria during aging, ischemia and post-ischemic recovery assessed by functional proteomics of enzymes
Roberto Federico Villa, Antonella Gorini, Federica Ferrari, Siegfried Hoyer
Neurochemistry International, 2013
ATP-ases of synaptic plasma membranes in striatum: Enzymatic systems for synapses functionality by in vivo administration of l-acetylcarnitine in relation to Parkinson's Disease
R.F. Villa, F. Ferrari, A. Gorini
Neuroscience, 2013
Energy metabolism of rat cerebral cortex, hypothalamus and hypophysis during ageing
R.F. Villa, F. Ferrari, A. Gorini
Neuroscience, 2012
Effect of CDP-choline on age-dependent modifications of energy- and glutamate-linked enzyme activities in synaptic and non-synaptic mitochondria from rat cerebral cortex
Roberto Federico Villa, Federica Ferrari, Antonella Gorini
Neurochemistry International, 2012
Functional proteomics of adenosine triphosphatase system in the rat striatum during aging
R. F. Villa, Federica Ferrari, A. Gorini
Neural Regeneration Research, 2012
Effect of in vivo l-acetylcarnitine administration on ATP-ases enzyme systems of synaptic plasma membranes from rat cerebral cortex
Roberto Federico Villa, Federica Ferrari, Antonella Gorini
Neurochemical Research, 2011

Federica Ferrari

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS